In specialty pharma — especially drugs with REMS programs, hub enrollment, or complex onboarding — patient start form (PSF) submissions and new patient initiation counts lead net product revenue recognition by weeks-to-months. These operational metrics provide a stronger 1-2 quarter forward signal than any revenue-based YoY comparison. An all-time high in patient starts that has not yet flowed through to reported revenue represents a loading event on the S-curve, not coincident momentum — and predicts revenue reacceleration in the next 1-2 quarters.
When analyzing specialty pharma companies, scan earnings releases and transcripts for patient initiation metrics (PSF counts, new patient starts, hub enrollments, specialty pharmacy new-fill counts). Prioritize these over revenue YoY when they diverge. A quarter showing revenue deceleration alongside accelerating patient starts is more likely an S-curve loading event (or a non-product revenue comp issue) than a demand signal. The absence of disclosed patient-start metrics is itself a yellow flag — companies with strong underlying demand typically disclose them.